Termination of pregnancy with mifepristone and misoprostol after the 11th week of pregnancy
Abstract
Background: The frequency of terminations of pregnancy (TOP) after the 11th week has been increasing, especially on the account of improvements in prenatal diagnostics. Therefore the methods used for TOP should be safe, efficient and acceptable for pregnant women. The new method for TOP with mifepristone and misoprostol (MI-MI) was introduced at the Division of Perinatology in 2007. The purpose of this study is to present the efficacy and safety of the method for termination of mid-trimester pregnancy. Methods: All women requiring TOP with MIMI for medical reasons were included in the study. They received 200 mg of mifepristone orally, 36–48 hours later 800 μg of misoprostol vaginally, followed by 400 μg buccally until the TOP. If placenta was retained, uterotonics were applied, and a decision was made whether to evacuate the uterus surgically. Before the discharge from hospital and 2–3 weeks after TOP we performed an ultrasound examination of the uterus. Results: A total of 174 women were enrolled in the study. The mean gestational age was 17.2 weeks (11–33 weeks). For 58 (33 %) women this was their first pregnancy. The method was successful in 173 (99.4 %) cases. The average time interval from the beginning of the procedure till TOP was 47.3 hours (13.8–168 hours). The average duration of hospital stay was 36.1 hours (25.0–61.5 hours). In 46 (26 %) cases surgical evacuation of the uterus after TOP was performed. Conclusions: We may conclude that TOP with mifepristone and misoprostol is efficient and safe.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
